Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Short term Debt: 2010-2025

Historic Short term Debt for Northwest Biotherapeutics (NWBO) over the last 13 years, with Sep 2025 value amounting to $9.7 million.

  • Northwest Biotherapeutics' Short term Debt rose 5.13% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year increase of 5.13%. This contributed to the annual value of $9.6 million for FY2024, which is 4.24% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Short term Debt stood at $9.7 million for Q3 2025, which was up 6.07% from $9.1 million recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Short term Debt peaked at $341.9 million during Q1 2021, and registered a low of $7.6 million during Q2 2024.
  • In the last 3 years, Northwest Biotherapeutics' Short term Debt had a median value of $9.1 million in 2025 and averaged $9.0 million.
  • Its Short term Debt has fluctuated over the past 5 years, first spiked by 2,723.95% in 2021, then slumped by 91.43% in 2023.
  • Northwest Biotherapeutics' Short term Debt (Quarterly) stood at $106.8 million in 2021, then dropped by 24.56% to $80.6 million in 2022, then plummeted by 88.59% to $9.2 million in 2023, then climbed by 4.24% to $9.6 million in 2024, then climbed by 5.13% to $9.7 million in 2025.
  • Its last three reported values are $9.7 million in Q3 2025, $9.1 million for Q2 2025, and $9.5 million during Q1 2025.